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Abstract
The impact of Panton-Valentine leukocidin (PVL) on the severity of complicated skin and skin structure infections (cSSSI)
caused by Staphylococcus aureus is controversial. We evaluated potential associations between clinical outcome and PVL
presence in both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) isolates from patients
enrolled in two large, multinational phase three clinical trials assessing ceftaroline fosamil for the treatment of cSSSI (the
CANVAS 1 and 2 programs). Isolates from all microbiologically evaluable patients with monomicrobial MRSA or MSSA
infections (n=473) were genotyped by PCR for pvl and underwent pulsed-field gel electrophoresis (PFGE). Genes encoding
pvl were present in 266/473 (56.2%) isolates. Infections caused by pvl-positive S. aureus were associated with younger
patient age, North American acquisition, and presence of major abscesses (P,0.001 for each). Cure rates of patients infected
with pvl-positive and pvl-negative S. aureus were similar overall (93.6% versus 92.8%; P=0.72), and within MRSA-infected
(94.5% vs. 93.1%; P=0.67) and MSSA-infected patients (92.2% vs. 92.7%; P=1.00). This finding persisted after adjustment for
multiple patient characteristics. Outcomes were also similar when USA300 PVL+ and non-USA300 PVL+ infections were
compared. The results of this contemporary, international study suggest that pvl presence was not the primary determinant
of outcome in patients with cSSSI due to either MRSA or MSSA.
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Introduction
Staphylococcus aureus is the leading cause of complicated skin and
skin structure infections (cSSSI) in the United States [1–4]. A
number of studies have reported a high prevalence of Panton-
Valentine leukocidin (PVL), a pore-forming, bi-component toxin
that causes neutrophil lysis [5], among bacterial isolates causing
cSSSI [6]. While the association between cSSSI and presence of
pvl is particularly strong with community-acquired methicillin-
resistant S. aureus (MRSA) [7], it has also been described among
methicillin-susceptible S. aureus (MSSA) isolates causing cSSSI
[3,8].
The role of PVL in determining the outcome and severity of S.
aureus cSSSI remains one of the most controversial topics in the
field of staphylococcal research [9]. The presence of pvl in S. aureus
strains has been associated with severe infections in some [10–15]
but not all [9,16,17] previous studies. For example, our group has
reported that pvl presence was paradoxically associated with a
better clinical outcome than cSSSI infections caused by pvl-
negative MRSA [17,18]. For this reason, the role of pvl in cSSSI is
unresolved.
The goal of the current study was to evaluate the impact of pvl
presence on the outcome of patients with cSSSI caused by both
MRSA and MSSA. To accomplish this goal, we used clinically
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cSSSI who were enrolled in two phase 3 multinational clinical
trials. The objectives of the current study were: 1) to confirm our
previous observations that pvl is not the primary determinant of
clinical outcome in patients with cSSSI due to MRSA, and 2) to
test whether this same finding is also encountered in MSSA-
infected patients. In addition, we aimed to evaluate whether
outcomes of infections caused by USA300 PVL+ isolates differed
from those caused by non-USA300 PVL+ isolates.
Methods
Patients and settings
CANVAS 1 (NCT00424190) and CANVAS 2 (NCT00423657;
Ceftaroline versus Vancomycin in Skin and Skin-Structure
Infection) were two methodologically identical, randomized,
double-blind, multinational phase 3 clinical trials that compared
the efficacy and safety of intravenous ceftaroline fosamil mono-
therapy with intravenous vancomycin plus aztreonam combina-
tion therapy for the treatment of adults with cSSSI caused by
gram-positive and gram-negative organisms. The study designs of
the CANVAS trials have been published in detail [19–21].
A total of 1378 patients from 111 participating centers in 12
countries were enrolled from February 2007 through December
2007 [19,20]. Men and non-pregnant women aged $18 years and
diagnosed with cSSSI severe enough to require initial hospitaliza-
tion or treatment in an emergency department and $5 days of
intravenous antimicrobial therapy and that involved either (1)
deep soft tissue or required deep surgical intervention, or (2)
cellulitis or abscess of a lower extremity in patients with diabetes
mellitus (DM) or well-documented peripheral vascular disease
(PVD), were eligible for the study. Purulent or seropurulent
drainage and/or collection or the presence of at least three of the
following signs or symptoms was also required for participation:
erythema, fluctuance, heat and/or localized warmth, pain and/or
tenderness to palpation, fever (temperature .38uC) or hypother-
mia, white blood cell (WBC) count of .10,000 / mm
3,o r.10%
immature neutrophils irrespective of WBC count.
Patients were randomized to receive either ceftaroline fosamil
(600 mg every 12 h) followed by normal saline placebo or
vancomycin followed by aztreonam (1 g each every 12 h) for 5–
14 days. Bacterial isolates were obtained from all patients at
baseline by needle aspiration or a surgical procedure. Test-of-cure
evaluation was performed 8 to 15 days after administration of the
last dose of the study drug. The clinical response at the test of cure
was classified as cure, failure, or indeterminate [21]. Clinical cure
was defined as total resolution of all signs and symptoms of the
baseline infection or improvement such that no further antimi-
crobial therapy was necessary. The microbiologically evaluable
(ME) population was defined as clinically evaluable patients with
$1 bacterial pathogen isolated from blood or the cSSSI site at
baseline, excluding patients whose baseline cultures revealed
monomicrobial Pseudomonas aeruginosa or anaerobic infection. In
the present investigation, the analysis population was defined as
microbiologically evaluable patients with cSSSI due to mono-
microbial S. aureus and a clinical response at test of cure evaluation.
The investigation was approved by the Duke University Medical
Center Institutional Review Board.
Pulsed Field Gel Electrophoresis
Pulsed-field gel electrophoresis (PFGE) with the restriction
enzyme SmaI was performed as previously described [22]. The
PFGE profiles were analyzed using BioNumerics software (Applied
Maths, Kortrijk, Belgium). A similarity coefficient of 80% was used
to define pulsed-field type clusters. Dice coefficients (pairwise
similarity) were calculated for each pair of isolates, and a
dendrogram was constructed using an optimization value of
0.50% and a position tolerance ranging from 1.25% to 1.35% (the
end of the fingerprint). PFGE profiles were interpreted according
to a published typing schema [22].
PCR assays for genotyping
S. aureus genomic DNA was extracted using an ultraclean
microbial DNA kit (MO BIO Laboratories, Inc., Carlsbad, CA) in
accordance with the manufacturer’s instructions. PCR assays were
used to screen the S. aureus genome for the putative bacterial
virulence toxin pvl for all S. aureus isolates using previously
described methods [17,18].
Statistical methods
Cure rate by pvl status was stratified by markers of severity,
including abscess versus non-abscess infection type, presence of
fever, white blood cells (.10,000/ mm
3), infection size (baseline
infection area of .100 cm
2), presence of diabetes, patient age, and
study medication. Infection size was calculated as the product of
the length and width of the primary infection site at its longest and
widest axes, respectively. Continuous variables were compared
between groups by using the two-sample t test. Categorical
variables were analyzed using Fisher’s exact test, its 2-by-K
extension, or the Cochran-Mantel-Haenszel test, as appropriate,
for stratified analyses. Our a priori hypothesis, that the presence of
pvl in MRSA cSSSI is not associated with a worse clinical outcome,
was tested using Fisher’s exact test. All reported P values are two
sided. P values of ,0.05 were deemed statistically significant.
Since subjects were not randomized on the basis of pvl status, all P
values calculated should be considered descriptive and not
inferential. Results were obtained using SAS software, version
9.1.3 (SAS Institute Inc, Cary, NC, USA).
Results
Study population and baseline characteristics
A total of 473 patients from the CANVAS studies with cSSSI
due to monomicrobial S. aureus (280 MSSA, 59.2%; 193 MRSA,
40.8%) and for whom clinical outcome were available, were
included in the current study. Among these 473 study patients, 253
(53.5%) received ceftaroline fosamil and 220 (46.5%) received
vancomycin plus aztreonam. Patients were predominantly white,
male, and North American, with an average age of 45 years. The
majority of infections were either major abscesses (202 [42.7%]) or
deep/extensive cellulitis (144 [30.4%]) (Table 1).
Patient characteristics according to pvl presence and
methicillin-susceptibility
Overall, pvl was detected in 266/473 (56.2%) of the S. aureus
isolates (Table 1; MRSA 164/193 [85.0%], MSSA 102/280
[36.4%]). In both the MRSA-infected and MSSA-infected cohorts,
presence of pvl was associated with younger age, and major abscess
(P,0.001). Patients with pvl-positive MRSA were significantly
more likely to be from North America, and less likely to have been
hospitalized or have PVD (all P,0.001) than patients with pvl-
negative MRSA infections. Patients with pvl-positive MSSA were
less likely to have other comorbid conditions, including DM
(P,0.001) or PVD (P=0.03) than patients with pvl-negative
MSSA infections.
PVL in MSSA and MRSA and Outcomes of cSSSI
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outcome
Overall, cure rates among patients with cSSSI due to pvl-
positive and pvl-negative S. aureus did not differ significantly (pvl-
positive S. aureus 93.6% [249/266] vs. pvl-negative S. aureus 92.8%
[192/207]; P=0.72). Cure rates remained similar when stratified
by methicillin-resistance (Table 2). Similar findings also persisted
in both the MRSA and MSSA populations after stratification by
infection type (abscess versus non-abscess), presence of fever,
leukocytosis, infection size (baseline infection area of .100 cm
2),
patient age, or DM (Table 2).
Table 1. Baseline characteristics of 473 patients with S. aureus complicated skin and skin structure infections (cSSSI) stratified by
methicillin-resistance and pvl gene status of the infecting pathogen.
Value for indicated patient group; n(%) except where noted













Mean age(yr) 6 SD 53.1617.2 40.6614.0 ,0.0001
** 51.2615.1 40.2616.0 ,0.0001**
Male 15 (51.7%) 96 (58.5%) 0.5440 119 (66.9%) 55 (53.9%) 0.0403
White race 27 (93.1%) 94 (57.3%) 0.0053 148 (83.1%) 87 (85.3%) 0.2357
Source of infection ,0.0001 ˆ ,0.0001 ˆ
Infected Wound 1 (3.4%) 19 (11.6%) 30 (16.9%) 6 (5.9%)
Major Abscess 4 (13.8%) 95 (57.9%) 46 (25.8%) 57 (55.9%)
Infected Ulcer 11 (37.9%) 0 (0.0%) 11 (6.2%) 2 (2.0%)
Infected Burn 10 (34.5%) 2 (1.2%) 6 (3.4%) 0 (0.0%)
Infected Bite 0 (0.0%) 9 (5.5%) 1 (0.6%) 3 (2.9%)
Deep/Extensive Cellulitis 2 (6.9%) 36 (22.0%) 72 (40.4%) 34 (33.3%)




Eastern Europe 20 (69.0%) 4 (2.4%) 94 (52.8%) 67 (65.7%)
Latin America 2 (6.9%) 3 (1.8%) 18 (10.1%) 1 (1.0%)
Western Europe 2 (6.9%) 0 (0.0%) 24 (13.5%) 8 (7.8%)
US 5 (17.2%) 157 (95.7%) 42 (23.6%) 26 (25.5%)
Prior antibiotic use ,0.00016 0.23236
No prior therapy 22 (75.9%) 52 (31.7%) 121 (68.0%) 59 (57.8%)
#24 hours of treatment 6 (20.7%) 84 (51.2%) 45 (25.3%) 34 (33.3%)
.24 hours of treatment 1 (3.4%) 28 (17.1%) 12 (6.7%) 9 (8.8%)
MRSA risk factors
Hospitalization 27 (93.1%) 73 (44.5%) ,0.0001 156 (87.6%) 85 (83.3%) 0.3704
Antibiotic use in 4 weeks prior 16 (55.2%) 111 (67.7%) 0.2071 62 (34.8%) 38 (37.3%) 0.6990
Diabetes Mellitus 4 (13.8%) 20 (12.2%) 0.7642 43 (24.2%) 7 (6.9%) 0.0003
Peripheral Vascular Disease 9 (31.0%) 2 (1.2%) ,0.0001 24 (13.5%) 5 (4.9%) 0.0250
Infection characteristics
Fever (temp of .38uC)




9 (34.6%) 72 (46.2%) 0.2954 49 (30.4%) 34 (41.5%) 0.1152
Baseline infection area of
.100 cm
2* *




8.0 9.5 0.1836 7.0 7.0 0.0054
Study medication 0.5401 1.0000
Ceftaroline 19 (65.5%) 94 (57.3%) 89 (50.0%) 51 (50.0%)
Vancomycin plus Aztreonam 10 (34.5%) 70 (42.7%) 89 (50.0%) 51 (50.0%)
*=P-Value from generalized 2-sided Fishers Exact Test. Calculated using 762 table (
‘), 462 table (1)a n d3 62 table (6).
**=P-Value from 2-sided T-test.
***=P-value from Wilcoxon Rank Sum test.
1=Subjects with missing data were not included in these summaries.
doi:10.1371/journal.pone.0037212.t001
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A total of 470 isolates successfully underwent PFGE genotyping
(three isolates failed smaI digestion). Of these 470 isolates, 231
(49.1%) were typeable by the USA typing schema. Among the
typeable isolates, 171 (74.0%) were USA300. Other strain types
identified included USA100 (2 isolates; 0.9%), USA200 (19
isolates; 8.2%); USA400 (6 isolates; 2.6%); USA600 (29 isolates;
12.6%); USA700 (1 isolate; 0.4%); and USA800 (3 isolates; 1.3%).
A comparison of infections caused by USA300 PVL+ with non-
USA300 PVL+ isolates (Table 3) demonstrated that USA300
PVL+ infections were associated with non-Caucasian ethnicity,
North America, prior antibiotic use, MRSA, and the absence of
hospitalization as a risk factor (all P,0.001). Neither the presence
of a deep abscess, the receipt of surgical intervention nor the
antibiotic regimen received differed between the two groups.
Outcomes from USA300 PVL+ and non-USA300 PVL+ infec-
tions were similar overall (P=0.80) and when stratified across
multiple sub-groups including methicillin-susceptibility (Table 4).
Discussion
The significance of PVL in the outcome of staphylococcal
infections remains unresolved. The present study used a large,
contemporary, multinational collection of MRSA and MSSA
isolates to evaluate the impact of pvl presence on clinical outcome
of patients with cSSSI. Despite adjustment for a number of
clinically relevant variables, pvl presence was not associated with a
higher risk of failure. This finding has several implications.
This analysis of the isolates collected in the CANVAS 1 and 2
studies add to an increasing body of evidence [17,18,23] that the
simple presence of pvl is not the primary outcome determinant in
all S. aureus infections. This finding persisted after adjusting for
patient comorbidities, infection type, infection severity, and patient
age. The results of this study are consistent with two previous
reports by our group evaluating potential associations between pvl
and cSSSI caused by MRSA [17,18]. However, the current
investigation extends our understanding of the role of pvl in
staphylococcal pathogenesis by considering its relevance in MSSA
infections. While pvl is currently considered primarily in the setting
of MRSA infections [1–4], its presence in MSSA is also well
established [3,6,8,24–26]. Collectively, these results underscore the
recent conclusions of Otto [9] that factors other than the mere
presence of pvl are the primary determinants of clinical outcome in
patients with S. aureus cSSSI.
However, the infections process is a continuum from onset to
resolution and while outcomes did not differ, the presence of pvl
was associated with important clinical characteristics in patients
with S. aureus cSSSI. Patients with pvl-positive cSSSI were younger,
more likely to have major abscess, more likely to be North
American and less likely to have health care contact, findings that
have been previously noted [17,26]. In contrast, patients with pvl-
negative strains tended to be older and have comorbidities such as
diabetes or peripheral vascular disease. These differences persisted
in both the MRSA and MSSA subgroups, and may reflect in part
the epidemiologic settings in which the infections were acquired.
Healthcare-associated S. aureus infections are less likely to contain
pvl [2] and are also more likely to cause cSSSI in older patients
with more comorbid conditions. By contrast, presence of pvl is
often associated with community-acquired infection. Thus, the
presence of pvl is associated with a different spectrum of disease in
a distinct subgroup of patients and also influences the treatment
received in that pvl+ cSSSI more frequently required surgical
management. However, the need for surgical intervention is a
clinical decision and prior knowledge of pvl status is unlikely to be
of assistance at the time this decision is made.
Following the provision of appropriate management, the
current investigation underscores the fact that pvl is not the
principle determinant of clinical outcome in patients with either
MRSA or MSSA cSSSI. Factors other than pvl should be
Table 2. Clinical outcome of cure for 473 patients with methicillin-resistant and methicillin-susceptible S. aureus complicated skin
and skin structure infections by pvl gene status, stratified by infection severity, diabetes, patient age, and study medication.
No. of cured patients/total no. of patients (%) with indicated status
MRSA (n=193) MSSA (n=280)





Overall 27/29 (93.1%) 155/164 (94.5%) 0.6722 165/178 (92.7%) 94/102 (92.2%) 1.0000
Type of infection
Abscess 3/4 (75.0%) 90/95 (94.7%) 0.2244 42/46 (91.3%) 53/57 (93.0%) 1.0000
Non-abscess 24/25 (96.0%) 65/69 (94.2%) 1.0000 123/132 (93.2%) 41/45 (91.1%) 0.7412




7/9 (77.8%) 68/72 (94.4%) 0.1306 45/49 (91.8%) 30/34 (88.2%) 0.7107
Baseline infection area of
.100 cm
2
21/22 (95.5%) 95/101 (94.1%) 1.0000 113/121 (93.4%) 59/60 (98.3%) 0.2753
Diabetes 3/4 (75.0%) 18/20 (90.0%) 0.4368 39/43 (90.7%) 7/7 (100.0%) 1.0000
Patient age (,65 y) 18/19(94.7%) 150/159(94.3%) 1.0000 136/145 (93.8%) 84/92 (91.3%) 0.6065
Study medication
Ceftaroline 17/19 (89.5%) 91/94 (96.8%) 0.1962 82/89 (92.1%) 46/51 (90.2%) 0.7578
Vancomycin plus Aztreonam 10/10 (100.0%) 64/70 (91.4%) 1.0000 83/89 (93.3%) 48/51 (94.1%) 1.0000
*=P-Value from generalized 2-sided Fishers Exact Test.
Missing categories are not in the analyses.
doi:10.1371/journal.pone.0037212.t002
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combating S. aureus cSSSI. For example, other characteristics
including alpha hemolysin [27], a new bicomponent leukotoxin
[28], the antagonistic effects of antibody to control proliferation of
PVL-producing S. aureus [29], and host species specificity of the
neutrophil lysis properties of PVL [30], may also be associated
with the clinical outcome of S. aureus cSSSI. It is also possible that
the genes coding for PVL may simply be markers of particular
bacterial clones and are not themselves directly involved in the
pathogenesis of more severe infection.
Due to the predominance of USA300 in North America as
previously described and also in this study, most reports regarding
PVL from this region focus on this strain of S. aureus. The
multinational nature of the CANVAS studies allowed us to
compare infections caused by USA300 PVL+ with non-USA300
PVL+ isolates. Despite some differences in epidemiology regarding
the likelihood of community-acquisition, deep abscesses were the
main clinical manifestation of both groups and, importantly, the
need for surgery and outcomes were equivalent. This suggests that
findings relating to the clinical manifestations and outcomes of
cSSSI due to USA300 are likely to be generalizable to other PVL+
Table 3. Baseline characteristics of 266 patients with pvl positive S. aureus complicated skin and skin structure infections (cSSSI)
stratified by pulsed-field gel electrophoresis type.








Mean age(yr)6 SD 40.1 (13.9) 41.1 (16.1) 0.6012
Male 90 (55.6) 61 (58.7) 0.7037
White race 94 (58.0) 87 (83.7) ,0.0001
Source of infection 0.0283
ˆ
Infected Wound 16 (9.9) 9 (8.7)
Major Abscess 99 (61.1) 53 (51.0)
Infected Ulcer 0 (0) 2 (1.9)
Infected Burn 0 (0) 2 (1.9)
Infected Bite 9 (5.6) 3 (2.9)
Deep/Extensive Cellulitis 35 (21.6) 35 (33.7)
Lower Extremity SSSI in Diabetic Subject 3 (1.9) 0 (0)
Geographical location ,0.0001
1
Eastern Europe 1 (0.6) 70 (67.3)
Latin America 0 (0) 4 (3.8)
Western Europe 0 (0) 8 (104)
US 161 (99.4) 22 (21.2)
Prior antibiotic use ,0.00016
No prior therapy 49 (30.2) 62 (59.6)
#24 hours of treatment 84 (51.9) 34 (32.7)
.24 hours of treatment 29 (17.9) 8 (7.7)
MRSA risk factors
Hospitalization 69 (42.6) 89 (85.6) ,0.0001
Antibiotic use in 4 weeks prior 108 (66.7) 41 (39.4) ,0.0001
Diabetes Mellitus 18 (11.1) 9 (8.7) 0.6779
Peripheral Vascular Disease 2 (1.2) 5 (4.8) 0.1144
Infection characteristics
Fever (temp of .38uC) 13 (8.0) 44 (42.3) ,0.0001
White Blood Cells .10,000 / mm
3 **, 76 (46.9) 30 (28.8) 0.1006
MRSA 141 (87) 23 (22.1) ,0.0001
Surgical intervention 115 (71.0) 64 (61.5) 0.7919
Study medication 0.5294
Ceftaroline 91 (56.2) 54 (51.9)
Vancomycin plus Aztreonam 71 (43.8) 50 (48.1)
*=P-Value from generalized 2-sided Fishers Exact Test. Calculated using 762 table (ˆ), 462 table (1)a n d3 62 table (6).
**=P-Value from 2-sided T-test.
doi:10.1371/journal.pone.0037212.t003
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America compared to PVL+ clones elsewhere in the world
remains unexplained and our data indicate that factors other than
PVL may play a more important role in the success of USA300.
The S. aureus isolates collections used in this study are large,
contemporary, multinational, cSSSI specific, and clinically char-
acterized to the level of rigor of a U.S. Food and Drug
Administration (FDA) registrational trial. Limitations include the
fact that we did not evaluate quantitative pvl expression or the
presence of pvl polymorphisms, as these properties may influence
the function of gene products [31,32], although pvl polymorphisms
have not been found to be of clinical importance [26]. By design,
this investigation focused only upon infections in which the
causative pathogen was available for culture. We were also unable
to consider potential relationships between vancomycin trough
levels and outcome.
In summary, this study has demonstrated that presence of pvl in
S. aureus strains is not associated with a worse outcome in patients
with cSSSI. This finding persisted regardless of methicillin-
resistance status. These findings indicate that factors other than
the presence of pvl are the primary determinants of clinical
outcome in S. aureus cSSSI. Future efforts are necessary for a more
complete understanding of the role of pvl in the pathogenesis of
serious infections due to S. aureus.
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